Hu Yong, Zhou Yongkang, Du Shisuo, Zhu Wenchao, Chen Yixing, Zeng Zhaochong
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, China.
Can J Gastroenterol Hepatol. 2024 Nov 21;2024:4696097. doi: 10.1155/cjgh/4696097. eCollection 2024.
The aim of this study was to explore the association between interleukin-6 (IL-6) concentration before radiotherapy (RT) and the prognosis after RT for patients with hepatocellular carcinoma (HCC). The clinical data for 101 patients with HCC who received RT from October 2016 to June 2021 were retrospectively analyzed. In these patients, the tumors were confined to the liver, and IL-6 concentration was measured before RT. The survival rate was calculated using the Kaplan-Meier method, and the Cox proportional hazards regression model was used to explore the independent factors affecting the patients' prognosis. -tile software was used to obtain the optimal cut-off value of pre-RT IL-6 concentration (7.8 pg/mL) for overall survival (OS). The 1-, 2-, and 3-year OS rates were 84.4%, 55.8%, and 34.7%, respectively, for patients with a pre-RT IL-6 concentration > 7.8 pg/mL versus 96.0%, 80.1%, and 80.1%, respectively, for those with a pre-RT IL-6 concentration ≤ 7.8 pg/mL. The OS rates of the two groups were significantly different ( < 0.001). The median progression-free survival (PFS) time was 7.5 months versus 15.1 months for patients with pre-RT IL-6 concentrations > 7.8 pg/mL and ≤ 7.8 pg/mL, respectively (=0.001). Pre-RT IL-6 concentration was an independent prognostic factor of OS (hazard ratio [HR] = 3.421, 95% confidence interval [CI]: 1.477-7.927, =0.004). Pre-RT IL-6 concentration (HR = 2.235, 95% CI: 1.176-4.246, =0.014) and age (HR = 0.615, 95% CI: 0.383-0.987, =0.044) were independent prognostic factors for PFS. The prognosis of HCC patients receiving RT was worse for those with a pre-RT serum IL-6 concentration > 7.8 pg/mL than those with a pre-RT serum IL-6 concentration ≤ 7.8 pg/mL. Pre-RT IL-6 concentrations may affect the prognosis of HCC patients.
本研究旨在探讨肝细胞癌（HCC）患者放疗（RT）前白细胞介素-6（IL-6）浓度与RT后预后之间的关联。回顾性分析了2016年10月至2021年6月期间接受RT的101例HCC患者的临床资料。这些患者的肿瘤局限于肝脏，且在RT前测量了IL-6浓度。采用Kaplan-Meier法计算生存率，并使用Cox比例风险回归模型探讨影响患者预后的独立因素。使用-tile软件获得RT前IL-6浓度（7.8 pg/mL）的总生存期（OS）最佳截断值。RT前IL-6浓度>7.8 pg/mL的患者1年、2年和3年OS率分别为84.4%、55.8%和34.7%，而RT前IL-6浓度≤7.8 pg/mL的患者分别为96.0%、80.1%和80.1%。两组的OS率有显著差异（<0.001）。RT前IL-6浓度>7.8 pg/mL和≤7.8 pg/mL的患者中位无进展生存期（PFS）时间分别为7.5个月和15.1个月（=0.001）。RT前IL-6浓度是OS的独立预后因素（风险比[HR]=3.421，95%置信区间[CI]：1.477-7.927，=0.004）。RT前IL-6浓度（HR=2.235，95%CI：1.176-4.246，=0.014）和年龄（HR=0.615，95%CI：0.383-0.987，=0.044）是PFS的独立预后因素。RT前血清IL-6浓度>7.8 pg/mL的HCC患者接受RT后的预后比RT前血清IL-6浓度≤7.8 pg/mL的患者更差。RT前IL-6浓度可能影响HCC患者的预后。
